Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study

Table 3

Statistical analysis of the mean differences in eGFR (mL/min/1.73 m²) at each assessment time points, including baseline, and at 3, 6, 9, 12, 15, and 18 months after initiating DPP4i.

Mean difference in eGFR	3 month ( value)	6 month ( value)	9 month ( value)	12 month ( value)	15 month ( value)	18 month ( value)
Baseline	−1.39 (0.010)	−1.26 (0.005)	−2.00 (0.001)	−1.96 (0.003)	−3.35 (<0.001)	−3.28 (0.001)
3 month		−0.55 (0.350)	−1.01 (0.124)	−1.19 (0.100)	−2.21 (0.010)	−3.38 (0.005)
6 month			−0.36 (0.189)	0.13 (0.551)	−1.88 (0.044)	−2.15 (0.013)
9 month				0.14 (0.823)	−0.49 (0.975)	−0.62 (0.384)
12 month					−1.63 (0.003)	−1.43 (0.152)
15 month						−0.39 (0.140)

Statistically significant difference at .